Conversion to resection post radioembolization in patients with HCC: recommendations from a multidisciplinary working group

Talia Barzel Baker*, Parissa Tabrizian, Ivan Zendejas, Thomas Clark Gamblin, Marwan Kazimi, Karim Boudjema, David Geller, Riad Salem

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Transarterial radioembolization (TARE) with yttrium-90 (90Y) glass microspheres is an efficacious option for converting appropriately selected patients with borderline-resectable hepatocellular carcinoma (HCC) to surgical candidacy. Methods: In 2018 and 2019, a diverse multidisciplinary group of surgical and interventional experts with experience using 90Y for downstaging and bridging to liver transplant convened to review peer-reviewed literature and personal experience in the use of 90Y to convert borderline resectable liver cancer patients to surgical candidacy. The working group included surgical oncologists specializing in liver cancer, liver transplant surgeons with experience in complex hepatobiliary surgery, and interventional radiologists with experience using 90Y. Results: This document presents expert recommendations based upon the group's experience and consensus. Conclusions: By combining related evidence from the literature with expert experiences with TARE in surgical candidates, these recommendations aim to demonstrate the safety, efficacy, and feasibility of TARE in converting borderline-resectable patients to surgical options. The document also addresses the concerns about potential complications associated with TARE during the surgical intervention.

Original languageEnglish (US)
JournalHPB
DOIs
StateAccepted/In press - 2022

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Conversion to resection post radioembolization in patients with HCC: recommendations from a multidisciplinary working group'. Together they form a unique fingerprint.

Cite this